KBC Group NV lessened its holdings in Alkermes Plc (NASDAQ:ALKS) by 22.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 210,271 shares of the company’s stock after selling 60,144 shares during the period. KBC Group NV’s holdings in Alkermes were worth $11,508,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of ALKS. Toronto Dominion Bank boosted its position in Alkermes by 12.7% in the 2nd quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock valued at $109,000 after buying an additional 212 shares during the period. SG Americas Securities LLC purchased a new position in Alkermes in the 4th quarter valued at approximately $114,000. Quantbot Technologies LP purchased a new position in Alkermes in the 3rd quarter valued at approximately $126,000. Virtu Financial LLC purchased a new position in Alkermes in the 3rd quarter valued at approximately $201,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Alkermes in the 3rd quarter valued at approximately $214,000. 98.89% of the stock is owned by institutional investors.

In related news, Director Paul J. Mitchell sold 1,000 shares of Alkermes stock in a transaction on Friday, December 1st. The shares were sold at an average price of $51.98, for a total transaction of $51,980.00. Following the sale, the director now directly owns 9,000 shares in the company, valued at approximately $467,820. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Shane Cooke sold 72,793 shares of Alkermes stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $60.55, for a total transaction of $4,407,616.15. Following the sale, the insider now owns 147,501 shares in the company, valued at $8,931,185.55. The disclosure for this sale can be found here. Insiders sold a total of 135,485 shares of company stock worth $8,227,502 over the last 90 days. Company insiders own 5.34% of the company’s stock.

Shares of Alkermes Plc (NASDAQ ALKS) opened at $54.69 on Wednesday. Alkermes Plc has a fifty-two week low of $46.42 and a fifty-two week high of $64.04. The firm has a market cap of $8,513.03, a price-to-earnings ratio of -49.27 and a beta of 1.94. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.05 and a quick ratio of 2.72.

A number of equities research analysts have recently weighed in on ALKS shares. Credit Suisse Group set a $66.00 price objective on shares of Alkermes and gave the company a “buy” rating in a report on Tuesday, November 28th. JPMorgan Chase & Co. set a $78.00 price objective on shares of Alkermes and gave the company a “buy” rating in a report on Friday, October 27th. Zacks Investment Research upgraded shares of Alkermes from a “hold” rating to a “buy” rating and set a $61.00 price objective on the stock in a report on Monday, January 8th. Mizuho set a $81.00 price objective on shares of Alkermes and gave the company a “buy” rating in a report on Saturday, October 21st. Finally, BidaskClub upgraded shares of Alkermes from a “sell” rating to a “hold” rating in a report on Friday, January 26th. Eight research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $64.17.

COPYRIGHT VIOLATION WARNING: This story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2018/02/14/kbc-group-nv-sells-60144-shares-of-alkermes-plc-alks.html.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes Plc (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.